RAPID RISK ASSESSMENT Outbreak of yellow fever in Angola, DRC and Uganda, first update – 27 May 2016
4
The virus can be detected in blood specimens by RT-PCR, antigen-capture or viral isolation. For primary arbovirus
infections, a serological diagnosis can be made by detecting specific IgM antibodies one week after infection (for
secondary arbovirus infections, IgM and IgG need to be detected) [15].
Prevention and outbreak control
Yellow fever is effectively prevented through vaccination with the live attenuated vaccine [4].
Mass vaccination campaigns are the most effective public health strategy to control yellow fever outbreaks. A
global vaccine stockpile is managed by the International Coordinating Group (ICG) on Vaccine Provision, which
functions as a revolving fund for epidemic response [16]. In the long term, introducing preventive immunisation
through routine childhood vaccination in endemic countries can significantly reduce the burden of the disease.
Yellow fever vaccination is recommended for travellers ≥9 months old to areas where there is evidence of
persistent or periodic yellow fever virus transmission [1]. The vaccine is recommended to protect individual
travellers at risk of exposure to yellow fever and to prevent international spread of the disease from endemic
countries to countries with competent vectors [1]. Some adverse effects associated with the vaccine have been
reported and a case-by-case assessment of the risks and benefits of yellow fever vaccination should be considered
for some risk groups, such as older people or those with underlying health conditions [17]. According to WHO
‘when considering vaccination, any traveller must take into account the risk of being infected with yellow fever
virus, country entry requirements, as well as individual risk factors (e.g. age, immune status) for serious vaccine-
associated adverse events’ [1]. To reduce the risk of serious adverse events, healthcare providers should be aware
of the contra-indications and follow the manufacturer’s guidance on the precautions to be considered before
administering yellow fever vaccine [2]. Complementary preventive measures, especially for travellers, include using
insect repellent and wearing protective clothing.
The period of protection provided by yellow fever vaccination, and the term of validity of the certificate has been
changed from 10 years to life, in accordance with a Word Health Assembly resolution, and this should come into
effect from July 2016. On 19 May 2016, the Emergency Committee of the International Health Regulations (2005)
advised for immediate application of the policy of one lifetime dose of yellow fever vaccine in light of the limited
worldwide vaccine supply [20].
Mosquito control contributes to prevention of yellow fever outbreaks and is critical in situations where vaccination
coverage is low or the vaccine is not immediately available. Mosquito control includes killing adult mosquitoes and
larvae by using insecticides and larvicides, as well as eliminating mosquito breeding sites. Community involvement
through activities, such as cleaning household drains and covering water containers where mosquitoes can breed,
is a very important and effective way to control mosquitoes, but requires some time for preparation and
implementation [4,21].
Possible shortage of yellow fever vaccine has been a concern for several years. According to the latest update from
UNICEF dated May 2016,
during 2015, UNICEF increased total aggregate awards to suppliers to reach
approximately 98 million doses for 2016–2017. However, whereas supply can meet emergency stockpile and
routine requirements, it is insufficient to meet all preventive campaign demands, which increased the total demand
through UNICEF to 109 million doses
[22]. According to Lucey and Gostin, a vaccine shortage can be anticipated if
yellow fever spreads to other countries or regions, especially if large urban populations are to benefit from mass
vaccination campaigns [23].
Event background information
Situation in Angola
On 21 of January 2016, WHO was notified by the IHR focal point in Angola of an ongoing yellow fever outbreak.
The first cases reported were two males living in the municipality of Viana, a densely populated municipality on the
outskirts of Luanda. The first case presented with yellow fever symptoms to a private clinic on 5 December 2015
[24]. In the following months, suspected cases were reported in all 18 provinces of Angola and confirmed cases
were reported in 14 provinces.
Yellow fever infection was initially confirmed in three patients by PCR at the Zoonosis and Emerging Disease
Laboratory of the National Institute for Communicable Diseases in Johannesburg, South Africa in early January and
then at the Pasteur Institute in Dakar, Senegal on 20 January 2016. Following the confirmation of yellow fever
infection cases in Luanda province and other provinces of Angola, the national reporting system was enhanced to
collect epidemiological information on suspected cases and samples for laboratory confirmation.
From 21 January to 22 May 2016, the Angolan Ministry of Health notified 2 536 yellow fever cases, of which 747
were confirmed and 301 fatal (case fatality ratio: 11.9%), 88 of these being among confirmed cases (CFR: 11.8%).
The epidemic curve (Figure 2) shows that the highest number of suspected and confirmed cases was reported in
February and March 2016, with a peak of notification of more than 80 confirmed cases reported per week at the
end of February. Since April, the number of new cases has declined in Angola and in the two most affected